An atopic dermatitis treatment for children and adolescents Dupixent is to be prescribed at general hospitals in South Korea.

A related industry source reported Sanofi Genzyme’s atopic dermatitis treatment Dupixent (dupilumab) 200 mg has been passed by drug committees at Seoul National University Hospital, National Medical Center, Korea University Ansan Hospital, Ulsan University Hospital, Chonnam National University Hospital, and Kangdong Sacred Heart Hospital. Other Big Five tertiary healthcare institutes are also currently reviewing the drug for prescription.

The low-dose (200 mg) Dupixent is indicated to treat adolescents aged over 12 weighing less than 60 kg with severe atopic d